Kornimate/medical-research-clean huggingface dataset:
tailored nutrition and food security interventions in comprehensive hiv care

Conditions: HIV; Food Insecurity; Malnutrition

Summary: the study hypothesizes that one form of food supplement to hiv-infected individuals in haiti (ready-to-use-supplementary food) will result in improved hiv, nutrition and quality of life outcomes when compared to a second type of food supplement (corn-soy-blend) over the course of 12 months of food supplementation.


Eligibility criteria:
inclusion criteria: * documented to have hiv infection by standard laboratory procedures * live in the geographic catchment area of pih services where study is taking place * 18 years of age or older * started antiretroviral therapy for hiv in the 24 months prior to study enrollment exclusion criteria: * if another household member is also eligible for food assistance * if subject is pregnant at the time of enrollment * if unable to give informed consent
exercise and two different kinesiotape applications in patients with sacroiliac joint dysfunction

Conditions: Sacroiliac Joint Dysfunction

Summary: this study is a randomized controlled study. 99 patients between the ages of 18-65 who were diagnosed with sacroiliac joint dysfunction will be included in the study.

33 patients will be given a home exercise program that strengthens the waist and hip girdle (to be shown once in the hospital by a physiotherapist and the form of the exercises will be given), 33 patients will be given kinesiotaping (kt) with ligament correction technique with the exercise program, and 33 patients will be given kinesiotaping with lymphatic correction technique with the exercise program. patients will do the exercises once a day for 1 month. kt will be repeated once a week for 3 weeks. when taping is performed, it will be kept for 5 days.the patients' pain at rest and during movement will be measured using the visuel analog scale (vas). patient global assessment and oswestry disability index (odi) will be questioned. evaluations will be performed before, 4th week and 1 month after treatment (8th week).

Eligibility criteria:
inclusion criteria: * patients with sacroiliac joint dysfunction between the ages of 18-65 exclusion criteria: * patients with rheumatological inflammatory disease * inflamatory sacroiliitis * patients with polyarthrosis, herniated disc, severe symptomatic disc degeneration, spinal stenosis and spondyloarthrosis. * patients with a history of pelvic trauma * patients with metabolic bone disease, infection, malignancy, pregnancy * patients with open wounds in the lumbar and sacral area
viscoelastic properties of lower extremity muscles in patients with hemophilia

Conditions: Hemophilia; Hemophilia A; Hemophilia B

Summary: the aim of our study is to evaluate the viscoelastic properties of lower extremity muscles in patients with hemophilia a and hemophilia b secondarily to compare them with their healthy peers.

hemophilia is a rare inherited coagulation disorder that develops as a result of factor viii (hemophilia a) or factor ix (hemophilia b) deficiency, and is a chronic group of diseases that mainly manifests with intra-articular (hemarthrosis) and intramuscular (hematoma) bleeding, affecting quality of life. the presence of easy ecchymosis formation in early childhood, especially intra-articular and intramuscular spontaneous bleeding, interventions and a history of bleeding that lasted longer than expected after trauma should suggest hemophilia. the severity of bleeding findings is directly related to the degree of deficiency of hemophilia a and b. hemarthroses due to bleeding in the joint (80%) and hematomas due to intramuscular bleeding (20%) cause joint degeneration and muscle atrophy. the joint in which hemarthrosis is most common is the knee joint, however, bleeding into the lower extremity muscles seriously affects the activities of daily living and lower extremity functionality. for this reason, the researchers aimed to evaluate the viscoelastic properties of lower extremity muscles in hemophilia patients and, secondarily, to compare them with their healthy peers.

Eligibility criteria:
inclusion criteria: * children aged 4-17 years * those who have been diagnosed with hemophilia a and hemophilia b by a physician * no history of acute bleeding * children who have family consent and volunteer to participate in the study exclusion criteria: * those with a history of lower extremity surgery * those with neurological disease * those with a history of lower extremity hemarthrosis or hematoma in the last 1 month * patients with inhibitor positive

Keywords: hemophilia muscle tone stiffness elasticity
effect of lifestyle modification on obese females with primary dysmenorrhea

Conditions: Primary Dysmenorrhea

Summary: the study will be designed to determine the effect of lifestyle modification on primary dysmenorrhea in obese females.

menstruation in women after puberty is often confused with dysmenorrhea. primary dysmenorrhea, where there is no apparent pelvic pathology, is characterized as painful menstrual cramps. this symptom typically occurs within one to two years of menarche and menstrual cycle stabilisation1. pain occurs a couple of hours before or after menstruation and lasts for 12 to 72 hours. dysmenorrhea can also be accompanied by nausea, discomfort, low back pain, or flank pain. obesity in women adolescents is one of the factors associated with dysmenorrhea also; endometrium production of physiological prostaglandin increased in primary dysmenorrhea. increased prostaglandin directly contributes to uterine contractions that eventually lead to primary dysmenorrhea. overweight and obesity thought to be correlated with dysmenorrhea by increasing the development of prostaglandin. the microbiome diet is a new, trendy weight loss diet. it created by dr. raphael kellman and based on eating and avoiding certain foods in the hopes of restoring gut health. it's also claimed to offer other benefits, such as a faster metabolism and weight loss. therefore, this study aims to investigate the effect of lifestyle modification on obese females suffering from primary dysmenorrhea

Eligibility criteria:
inclusion criteria: * young females with moderate to severe primary dysmenorrhea (visual analogue scale \> 4). * virgin, nonsmokers. * young female aged from 18-25 years with bmi more than 30 kg/m². * they have regular menstrual cycles (a menstrual flow of 38 days, with 21-35 days between menstrual flows) * they have not practiced sports for at least one year before entering the study. * they have not engaged in diet for at least one year before entering the study. exclusion criteria: * any participant having secondary dysmenorrhea (associated with identifiable pelvic pathology). * any participant with a history of pelvic inflammatory disease, myoma and tumors, pelvic infection, ovarian cyst, any gynecological disease. * any participant with a history of previous spinal surgeries. * any participant with a history of anemia, diabetes, hypertension, cardiovascular disease, thyroid disease, neurological disorder, rheumatoid arthritis, bariatric surgery, or taking weight loss medication.
cellular immunity and renal cell cancer

Conditions: NK Cell Mediated Immunity; NK Cell Cytokine Production; Kidney Cancer

Summary: renal cell cancer (rcc) is one of the most important urogenital tumors because of it's high mortality and increasing incidence. rcc, which accounts about 3% of all malignant tumors in the adults, is the most lethal urogenital cancer. the high mortality rate stimulate investigator groups to study rcc pathogenesis including immunological part. it is interesting that immunotherapy was firstly started in patients with metastatic rcc using il-2 and interferon gamma. the first results were promising but the exact mechanism of acting was not found. in the rcc, as in the others tumors, immune cells (t lymphocytes, nk and nkt cells) are responsible for main antitumor effect. their effect was caused by cytotoxic activity on the tumor cells. in the investigation investigators will determine patterns of aggregation of tumor infiltrating immune cells in the blood, healthy kidney and carcinomatous tissue. but, presence of this cells not implicated that this cells are active. their activity will be determined by proofing cytotoxicity of different subgroup of immune cells. in that way investigators will present different patterns of aggregation of tumor infiltrating immune cells and their cytotoxicity which will direct that this cells are active with antitumor effect. correlation of collected data with classical prognostic factors in the patients with rcc as tumor staging, tumor grading (fuhrman) and histological subtype will help to determine some immunological factors as possible new prognostic factors. for conclusion, the results of this study will allow better understanding of rcc pathogenesis, specially their immunological part and become a foundation for the future investigations.

cellular immunity will be investigated in the two group of patients: operated patients with rcc and healthy volunteers. in the study investigators will determine patterns of aggregation of tumor infiltrating immune cells in the blood (rcc patients and volunteers), healthy kidney and carcinomatous tissue as their cytotoxicity (only rcc patients). investigators will determine: 1. presence of different immune cells in the blood and kidney tissue (t lymphocytes, nk cells, nkt cells, t regulatory cells), 2. presence and distribution of cytolytic molecule perforin and granulysin in immune cells (t lymphocytes, nk cells, nkt cells) in the blood, kidney tissue and urine 3. nk cytotoxicity 4. possible correlation between presence of immune cells and clinical prognostic factors

Eligibility criteria:
inclusion criteria: * rcc (renal cell cancer) patients * operated patients * both gender * older than 18 years * written informed consent exclusion criteria: * age younger of 18 * patients with metastatic disease * patients receiving antibiotics 6 weeks before operation * patients regularly treated with corticosteroids or immunosuppressive drugs * transplanted patients * patients with autoimmune diseases and/or vasculitis

Keywords: renal cell cancer nk cells tumor infiltrating lymphocytes cellular immunity
evaluation of gait symmetry in upper extremity burn injuries

Conditions: Burn Injury

Summary: thirty patients with unilateral burn injury, and 60 healthy subjects will be included in this study. participants with burn injury will evaluate with the following assessment tools: demographic data; age, gender, height, body mass index; burn characteristics; type of burn injury, degree of burn injury, localization of burn injury and total burn surface area will be recorded. gait parameters (step length, stride length, base support, step time, cycle time, cadence, velocity, single support, double support, swing ( % of gait cycle) and stance (% of gait cycle). will be recorded via computerized system. and gait symmetry will be calculated via formule. participants' kinesiophobia level will be evaluated with tampa kinesiophobia scale. their pain will be assessed by visual analog scale. their arm swing will be evaluated by a scale.

thirty individuals with lower extremity burn injury and sixty healthy subjects will be included in this study. participants with burn injury will be included if they are aged of 18-50, able to walk independently at least 10 meters. healthy subjects will be included if there are no orthopedic, neurological or musculoskeletal disorders that affect gait. 1. group: 30 patients with burn injury 2. group: 30 healthy subjects (when evaluating the gait analysis, their arm will not be restricted (their natural walking) 3. group : 30 healthy subject (when evaluating the gait analysis, their arm will be restricted ) participants will evaluate with the following assessment tools: demographic data; age, gender, height, body mass index; burn characteristics; type of burn injury, degree of burn injury, localization of burn injury and total burn surface area will be recorded. all subjects' gait analysis will be conducted via gaitrite (computerized) system. gaitrite system for gait parameters (step length, stride length, base support, step time, cycle time, cadence, velocity, single support, double support, swing ( % of gait cycle) and stance (% of gait cycle), tampa kinesiophobia scale for kinesiophobia level, visual analog scale for pain, a scale that developed by us for arm swing will be used. these evaluations will be applied one time for participants. these evaluations will be made within 5 days following burn injury.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of upper extremity burn injury * must be able to walk independently * control group consists of healthy adults with the similar demographic characteristics as experimental group. exclusion criteria: * walking with assist device * having a visual deficits * having an orthopedic problems that affect gait * having a neurological disorders * having a musculoskeletal disorders that affect gait * having an undergone orthopedic surgery

Keywords: burn injury gait symmetry arm swing
outcomes of concomitant bypass surgery in septal myectomy

Conditions: Hypertrophic Cardiomyopathy; Coronary Artery Disease; Myocardial Bridging

Summary: to investigate clinical characteristics and survival outcomes of patients with obstructive hypertrophic cardiomyopathy who underwent concomitant coronary artery bypass grafting during septal myectomy.

surgical septal myectomy (sm) is an effective approach for treating patients with drug-refractory obstructive hypertrophic cardiomyopathy (hcm).however, numerous patients with hcm exhibit concurrent ischemic heart disease, including atherosclerotic coronary artery disease (cad) and myocardial bridging (mb). although patients with hcm have been known to possess diminished coronary flow reserve,additional cad can worsen myocardial ischemia, contributing to an unfavorable prognosis.mb, although infrequent, may affect diastolic heart perfusion, leading to angina and even sudden death.current guidelines recommend revascularization for ischemic heart disease caused by cad and mb.however, the impact of concomitant coronary revascularization during hcm management remains unclear. in this study, we analyzed the clinical characteristics and surgical scenarios of patients who underwent concomitant coronary artery bypass grafting (cabg) during ventricular sm and investigated their prognosis. patient clinical and survival data from 2009-2020 were retrospectively reviewed. the median follow-up period was 5.1 years. all-cause mortality was the primary endpoint.

Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of obstructive hypertrophic cardiomyopathy. 2. undergo ventricular septal resection and cardiac bypass surgery at the same time. exclusion criteria: incomplete surgical and follow-up data
manufacture of clinical t-cell products for future treatment

Conditions: Virus-specific T Cells

Summary: the aim of this pilot study is to validate the manufacture of t-cell products using gmp-approved reagents for future clinical use. lymphocytes from whole blood of max 300ml from volunteers or from total 9 volunteer apheresates will be isolated to validate the protocol under good manufacturing practice (gmp).

viral diseases occur in up to 50% of patients after transplantation. in most cases, there is a reactivation of the virus, which can be found latent or dormant in the body's own cells. the main reason for the occurrence of these diseases is the limited t-cell immunity, which serves to control these viruses in healthy people. to date, there are few effective and, depending on the virus, no established therapies. in addition, the established therapies are often associated with considerable toxicity. an alternative therapy, which has already shown success in the 1990s, is the administration of virus-specific t cells. adoptive t cell therapies for the major pathogens emerging post-transplant are intended to use. in order to be used as therapy these cells must be manufactured under good manufacturing practice (gmp). leukapheresis from whole blood of maximum 300ml is used to generate the virus-specific t cells. these cells are examined for purity and specificity and are used for scientific purposes only. the aim of this study is to validate the manufacture of t-cell products using gmp-approved reagents for future clinical use.

Eligibility criteria:
inclusion criteria: * signed informed consent * immunoglobulins (ig) g available for epstein-barr virus (ebv) or cytomegalovirus (cmv) * detectable t-cell response for ebv or cmv measured by flow cytometry (\> 0.01%) exclusion criteria: * infection with human immunodeficiency virus (hiv), hepatitis b virus (hbv), hepatitis c virus (hcv) or human t-cell lymphoma virus (htlv)-i/ii

Keywords: t cell immunity adoptive t cell therapy good manufacturing practice (gmp) leukapheresis
a study to collect information about the use of redifferentiating medications as a standard treatment for thyroid cancer

Conditions: Thyroid Cancer; Thyroid; Refractory Thyroid Cancer

Summary: the purpose of this study to learn more about the use of redifferentiating medications as a standard treatment for radioactive iodine/rai-refractory thyroid cancer. this study is a registry study.


Eligibility criteria:
inclusion criteria: * patients ≥ 18 years old at time of consent inclusion criteria: * patients diagnosed with rai refractory thyroid cancer or unlikely to respond to rai. * patients who will receive redifferentiation agents prior to planned diagnostic and/or therapeutic use of radioactive iodine as part of routine clinical care. * patients who have never received redifferentiation agents outside of a clinical trial or have received redifferentiation agents in the context of a clinical trial will be enrolled after the clinical team has decided to proceed with a redifferentiation agent as part of routine clinical care prior to diagnostic and/or therapeutic radioactive iodine administration. * patients previously treated with redifferentiation agents as part of clinical care prior to diagnostic and/or therapeutic radioactive iodine administration who are willing to provide retrospectively collected data surrounding the time of the previous treatment and will provide prospective data from the time of consent. exclusion criteria: * rai refractory thyroid cancer patients that will receive redifferentiation agents prior to diagnostic and/or therapeutic use of radioactive iodine as part of a prospective clinical trial.

Keywords: rai refractory thyroid cancer thyroid cancer thyroid refractory thyroid cancer radio-iodine refractory thyroid cancer 22-320 memorial sloan kettering cancer center
magnetic resonance imaging and neuro-psychological testing in cystic fibrosis

Conditions: Cystic Fibrosis

Summary: cf is a complex, inherited illness that can affect many organs of the body. the investigators have found that some patients with cf have reported more problems with memory than would be expected at their age and that patients appear to be using memory strategies to overcome memory loss. the investigators intend to objectively test memory and examine mri images of the brain of patients with cf.

patients with cf have several potential risk factors which may predispose them to memory problems. because the cf population has historically only been young, this is not something that has been focused on. no research has currently identified whether patients with cf have a much earlier risk of developing cognitive impairment or how cf impacts on the brain. there has not previously been work in this area of cf and the investigators are in a unique position with the cardiff university brain research imaging centre (cubric) and its expertise to be able to perform magnetic resonance imagining (mri) scans and neurocognitive testing on patients with cf for the first time.

Eligibility criteria:
inclusion criteria: * male or female, aged greater or equal to 30 years * a diagnosis of cf * primary school education or above * able to provide informed consent exclusion criteria: * contraindications to mri as found on the cubric screening form (including presence of indwelling metal devices/clips) * existing neurological disease affecting cognition (including stroke and traumatic brain injury) * existing diagnosis of dementia documented in medical notes * vascular complications of diabetes * requiring supplemental oxygen -long term or overnight * hepatic failure * overt psychiatric disorders * past or present alcohol or recreational drug misuse * pregnancy * current infection smoker
alicaforsen (isis 2302) in patients with active crohn's disease

Conditions: Crohn's Disease

Summary: isis 2302 is an antisense oligonucleotide drug that reduces the production of a specific protein called intercellular adhesion molecule (icam-1), a substance that plays a significant role in the increase of inflammation. people with crohn's disease have been shown to over-produce icam-1 in their gut tissues. alicaforsen works by blocking icam-1 messenger rna, the "instruction" molecule that is required for the production of icam-1 protein. this trial will examine effects of alicaforsen delivered by 2-hour intravenous infusion over a four-week period, compared to a placebo. patients may remain on stable background 5-asa, antibiotic, or immunosuppressive drugs, and prednisone (or equivalent) at \</= 30 mg per day.


Eligibility criteria:
inclusion criteria 1. age \>/= 12 years 2. weight \>/= 36 kg 3. cdai score of 220 - 400 4. documentation of crohn's disease activity by endoscopy, biopsy or imaging in the last 2 years 5. no tnf-α inhibitor treatment for three months prior to first study drug infusion exclusion criteria 1. known severe, fixed, symptomatic stenosis of the small or large intestine with significant dilation 2. extensive external fistulization (\> 3 external fistulae which are expressible with gentle compression); colostomy or ileostomy 3. active infection, including infectious colitis, or infection with hiv, hepatitis b or hepatitis c 4. malignancy within 3 years or poorly controlled medical illness 5. requires intravenous heparin therapy or with a history of a bleeding problem

Keywords: crohn's
probiotics as adjuvant treatment for bacterial vaginosis

Conditions: Bacterial Vaginosis

Summary: the investigators are trying to determine if oral probiotics (umeta-miyue, lactobacillus rhamnosus gr-1 and lactobacillus reuteri rc-14) (30 days)with metronidazole vaginal suppositories(7 days) is better than using metronidazole vaginal suppositories only in preventing the recurrence of bacterial vaginosis (bv).

studies have shown that oral probiotics can significantly promote the recovery of vaginal flora mainly because intestinal microbiota can migrate and affect vaginal microecology. this project aims to evaluate the efficacy of oral probiotics (umeta-miyue, lactobacillus rhamnosus gr-1 and lactobacillus reuteri rc-14) (30 days) with metronidazole vaginal suppositories(7 days) in the treatment of bacterial vaginosis and to explore the correlation between vaginal flora and fecal flora by detecting the metagenomics of vaginal secretions and intestinal feces at the time of baseline phase, the first month after treatment, the third month after treatment and the sixth month after treatment.

Eligibility criteria:
inclusion criteria: 1. aged 18 to 65 years old, with history of sexual activity, premenopausal women； 2. nugent score ≥ 7 for diagnosing bv； 3. sign informed consent. exclusion criteria: 1. mixed vaginitis, such as vulvovaginal candidiasis (vvc), trichomonas vaginalis (tv) infection, chlamydia trachomatis (ct) infection or gonococcal vaginitis; 2. history of systemic organic diseases or psychiatric diseases; 3. planning for or during pregnancy, lactation, menstruation; 4. within 5 days of onset of the disease, any antibiotics has been used; 5. long-term use of contraceptives or immunosuppressant; 6. anaphylactic constitution or allergic to known ingredients of research drugs.